The Stanford University Medical Center has provided preoperative Prostate Specific Antigen (PSA) data on 97 patients who are about to undergo radical prostatectomy (complete prostate removal) for the treatment of prostate cancer. The American Cancer Society (ACS) estimates that nearly 30,000 American men died of prostate cancer in 2014 (http://www.cancer.org/). PSA is a protein that is produced by the prostate gland and is found in the bloodstream. The goal is to develop a predictive model of PSA among the provided set of clinical measures. PSA can be an effective prognostic indicator, among others, of how well a patient can and should do after surgery. The patient's PSA levels are measured at various intervals after the surgery and used in various formulas to determine if a patient is cancer-free. A preoperative predictive model in conjunction with the postoperative data (not provided here) can possibly improve cancer care for thousands of men each year.